Connect Biopharma (ADR) (CNTB)
Develops rademikibart for asthma and COPD outside Greater China.
$2.80
Pre-market+0.03 (+1.27%)
At close$2.77(+17.16%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions46 holders · as of Mar 31, 2026 | 20.24% | 12.75M ADS | |
| Insiders9 holders · as of Jul 1, 2026 | 37.95% | 23.90M ADS | |
| Strategic holders3 holders · as of Apr 14, 2026 | 36.74% | 23.14M ADS | |
| Otherremainder | 5.07% | 3.20M ADS |
62.97M ADS as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Institutions13F, as of Mar 31, 2026
46 holders · 12.75M shares · 15 new positions · 23 increased · 8 reduced · 4 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Ikarian Capital, LLC | 5.39M | 8.56% | +600.0K | May 15, 2026 |
| Boothbay Fund Management, LLC | 1.23M | 1.96% | 0 | May 15, 2026 |
| 683 Capital Management, LLC | 900.0K | 1.43% | +900.0Knew | May 15, 2026 |
| Perceptive Advisors LLC | 792.7K | 1.26% | 0 | May 29, 2026 |
| Adar1 Capital Management, LLC | 742.4K | 1.18% | +742.4Knew | May 18, 2026 |
| Richmond Brothers, Inc. | 476.6K | 0.76% | +303.1K | May 11, 2026 |
| Millennium Management LLC | 474.6K | 0.75% | +427.6K | May 15, 2026 |
| BML Capital Management, LLC | 408.9K | 0.65% | 0 | May 6, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Panacea Innovation Limited | 25.10% | 13.95M | 13D | Jul 21, 2025 ↗ |
| BioFortune Inc | 9.50% | 5.99M | 13G | Apr 14, 2026 ↗ |
| Zheng Wei | 9.00% | 5.02M | 13G | Feb 17, 2026 ↗ |
| Ikarian Capital, LLC | 8.80% | 4.93M | 13G | Feb 17, 2026 ↗ |
| Wei Zheng | 6.20% | 3.88M | 13G | May 15, 2026 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| May 29, 2026 | James Huangdirector | Purchase | 150,000 | $2.48 | 13,310,000 |
| Mar 31, 2026 | James Huangdirector | Purchase | 1,160,000 | $3.45 | 13,160,000 |
CongressHouse and Senate disclosures
Not reported.